Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-30

Astria Therapeutics (ATXS)

CEO Jill Milne was paid $6,604,416 in fiscal year 2024, ↑ up 123.5% from fiscal year 2023, the 75th percentile of its disclosed peer group (SEC filing 0001104659-25-040180 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$6,604,416 ↑
Jill Milne total, FY2024
75th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
86.82%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jill Milne (President and Chief Executive Officer), FY2024 total compensation $6,604,416 (base salary $637,868) [exec_comp, SEC accession 0001104659-25-040180, filed 2025-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jill Milne$637,868$0$0$5,637,078$318,934$0$10,536$6,604,416
President and Chief Executive Officer
Christopher Morabito485,920001,789,892194,368010,5362,480,716
Chief Medical Officer
Benjamin Harshbarger461,617001,789,892184,647011,7772,447,933
Chief Legal Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Jill Milne$6,604,416$2,955,504—↑ +3,648,912
Christopher Morabito2,480,7161,321,586—↑ +1,159,130
Benjamin Harshbarger2,447,9331,297,491—↑ +1,150,442

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Astria Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ATXS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against ATXS
9 companies name ATXS as a compensation peer

Each company listed discloses ATXS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATXS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Benjamin HarshbargerGeneral Counsel$2,447,933
Jill MilneCEO$6,604,416
Christopher MorabitoChief Medical Officer$2,480,716
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Fred CalloriIndependent Director$135,980
Gregg LapointeIndependent Director$146,980
Hugh ColeIndependent Director$135,730
Joanne BeckIndependent Director$139,480
Jonathan ViolinIndependent Director$141,980
Kenneth BateChair of the Board$177,480
Michael KishbauchIndependent Director$140,980
Sunil AgarwalIndependent Director$256,282
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Gregg LapointeDirector2025-06-11A26,550$0$0Derivative, Class A CommonForm 4 ↗
Sunil AgarwalDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Joanne BeckDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2025-06-11A26,55000Derivative, Class A CommonForm 4 ↗
Andrew KomjathyChief Commercial Officer2026-01-23D10——CommonForm 4 ↗
Andrea MatthewsChief Business Officer2026-01-23D262,500——Derivative, Class A CommonForm 4 ↗
Andrea MatthewsChief Business Officer2026-01-23D32,812——Derivative, Class A CommonForm 4 ↗
Jill C. MilneDirector2026-01-23D4,377——CommonForm 4 ↗
Christopher MorabitoChief Medical Officer2026-01-23D262,500——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2026-01-23D16,666——Derivative, Class A CommonForm 4 ↗
Joanne BeckDirector2026-01-23D16,666——Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2026-01-23D16,666——Derivative, Class A CommonForm 4 ↗
Gregg LapointeDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Joanne BeckDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Joanne BeckDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Joanne BeckDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Noah ClauserChief Financial Officer2026-01-23D262,500——Derivative, Class A CommonForm 4 ↗
Noah ClauserChief Financial Officer2026-01-23D55,000——Derivative, Class A CommonForm 4 ↗
Andrew KomjathyChief Commercial Officer2026-01-23D225,000——Derivative, Class A CommonForm 4 ↗
Andrew KomjathyChief Commercial Officer2026-01-23D55,000——Derivative, Class A CommonForm 4 ↗
Andrew KomjathyChief Commercial Officer2026-01-23D45——Common, indirectForm 4 ↗
Gregg LapointeDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Gregg LapointeDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Gregg LapointeDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Gregg LapointeDirector2026-01-23D16,666——Derivative, Class A CommonForm 4 ↗
Andrea MatthewsChief Business Officer2026-01-23D20,000——Derivative, Class A CommonForm 4 ↗
Jill C. MilneDirector2026-01-23D761,000——Derivative, Class A CommonForm 4 ↗
Jill C. MilneDirector2026-01-23D195,000——Derivative, Class A CommonForm 4 ↗
Christopher MorabitoChief Medical Officer2026-01-23D80,000——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23A14,100——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23A14,100——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23A8,333——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23A14,166——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23D263,321——CommonForm 4 ↗
Benjamin HarshbargerChief Legal Officer2026-01-23D262,500——Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Andrew KomjathyChief Commercial Officer2026-01-23D45——Common, indirectForm 4 ↗
Joanne BeckDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Kenneth BateDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2026-01-23D14,100——Derivative, Class A CommonForm 4 ↗
Sunil AgarwalDirector2026-01-23D26,550——Derivative, Class A CommonForm 4 ↗
Sunil AgarwalDirector2026-01-23D28,200——Derivative, Class A CommonForm 4 ↗
Jonathan ViolinDirector2026-01-23A26,550——Derivative, Class A CommonForm 4 ↗
Benjamin HarshbargerChief Legal Officer2026-01-23D55,000——Derivative, Class A CommonForm 4 ↗
Benjamin HarshbargerChief Legal Officer2026-01-23D33,333——Derivative, Class A CommonForm 4 ↗
Michael KishbauchDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Hugh ColeDirector2026-01-23D16,666——Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2026-01-23D8,333——Derivative, Class A CommonForm 4 ↗
Fred CalloriDirector2026-01-23D14,166——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Jill MilneOption534,60015.26—
Christopher MorabitoOption39,5833.87—
Benjamin HarshbargerOption48,75013.36—
Jill MilneOption56,8756.51—
Benjamin HarshbargerOption4,16412.96—
Christopher MorabitoOption48,75013.36—
Benjamin HarshbargerOption16,0426.51—
Jill MilneOption148,95813.36—
Jill MilneOption19,44417.22—
Christopher MorabitoOption175,00015.26—
Benjamin HarshbargerOption5,55617.22—
Benjamin HarshbargerOption175,00015.26—
05

Incentive-plan design — the Compensation Discussion & Analysis

We consider compensation for comparable positions in the market, historical compensation levels, individual performance, and our desire to motivate executives to achieve short- and long-term results in the best interests of stockholders. We do not target a specific mix of compensation among base salary, bonus, or equity incentives.

CEO STI target (% of salary)50%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-1143,538,6926,611,4515,13986.82%Passed
20242024-06-0540,882,8885,346,9246,44888.43%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-06-1186.82%a
20242024-06-0588.43%b

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Sunil AgarwalIndependent · Science and Technology$34,973$0$221,309—$0$256,282
Kenneth BateIndependent · Board Chair · Audit90,500086,980—0177,480
Gregg LapointeIndependent · Audit (Chair)60,000086,980—0146,980
Jonathan ViolinIndependent · Science and Technology (Chair)55,000086,980—0141,980
Michael KishbauchIndependent · Compensation (Chair)54,000086,980—0140,980
Joanne BeckIndependent · Compensation · Science and Technology52,500086,980—0139,480
Fred CalloriIndependent · Compensation49,000086,980—0135,980
Hugh ColeIndependent · Audit · Compensation48,750086,980—0135,730
Jill C. MilneEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$444,723
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$444,723

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Astria Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Astria Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Edgewise Therapeutics, Inc.2025Kevin Koch$670,000$1,171,625$5,041,621$462,300$7,359,546
2Viridian Therapeutics, Inc.2025Stephen Mahoney700,0001,058,0984,381,713630,0006,776,249
3Astria Therapeutics2024Jill Milne637,86805,637,078318,9346,604,416
4Savara, Inc.2025Matthew Pauls660,0003,870,0000297,0004,845,000
5Ocugen, Inc.2025Shankar Musunuri757,9002,194,4451,385,87104,841,822
6Annexon Biosciences2025Douglas Love670,83302,522,260371,2503,579,202
7Larimar Therapeutics, Inc.2025Carole Ben-Maimon650,000660,8601,889,16003,526,423
8Inozyme Pharma, Inc.2024Douglas Treco541,66701,933,37502,485,392
9Foghorn Therapeutics, Inc.2025Adrian Gottschalk638,00001,334,037385,9902,361,027
10Adicet Bio, Inc.2025Chen Schor646,2940512,079284,5921,465,747
11Cue Biopharma, Inc.2025Usman Azam143,07701,042,31301,185,639
—Rallybio——————not in coverage universe
—Third Harmonic Bio——————not in coverage universe
—Werewolf Therapeutics, Inc.——————not in coverage universe
—Vigil Neuroscience, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Astria Therapeuticsnot disclosedOption 100not disclosedAon
Adicet Bio, Inc.not disclosednot disclosednot disclosedAon Consulting, Inc.
Annexon Biosciences100% of target%not disclosednot disclosedAlpine Rewards
Cue Biopharma, Inc.not disclosedOption 100not disclosedRadford, an AON Hewitt company
Edgewise Therapeutics, Inc.not disclosednot disclosednot disclosedAlpine
Foghorn Therapeutics, Inc.not disclosedOptions 100not disclosedPay Governance, LLC
Inozyme Pharma, Inc.not disclosednot disclosednot disclosedAlpine Rewards
Larimar Therapeutics, Inc.not disclosedOption 75 · RSU 25NoAon
Ocugen, Inc.not disclosednot disclosednot disclosedPearl Meyer & Partners LLC
Rallybionot disclosednot disclosednot disclosednot disclosed
Savara, Inc.90%RSU 100not disclosedAon
Third Harmonic Bionot disclosednot disclosednot disclosednot disclosed
Vigil Neuroscience, Inc.not disclosednot disclosednot disclosednot disclosed
Viridian Therapeutics, Inc.150%Options 75 · RSU 25not disclosedCompensia
Werewolf Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Astria Therapeutics in fiscal 2024?
As disclosed, Jill Milne (President and Chief Executive Officer) was the highest-paid executive at Astria Therapeutics in fiscal 2024, with total compensation of $6,604,416.
How does Astria Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Jill Milne's total compensation ranked at the 75th percentile of Astria Therapeutics's disclosed peer group.
How did shareholders vote on Astria Therapeutics's executive compensation?
As disclosed, 86.82% of shareholders supported Astria Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Astria Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Astria Therapeutics reported total board compensation of $444,723 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jill MilneDEF 14A2025-04-280001104659-25-040180Section “Executive Compensation”. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460
2Section 01, Christopher MorabitoDEF 14A2025-04-280001104659-25-040180Section “Executive Compensation”. As printed: 2,480,716. Filing ↗machine: r3 · c35 · span 334778–334787
3Section 01, Benjamin HarshbargerDEF 14A2025-04-280001104659-25-040180Section “Executive Compensation”. As printed: 2,447,933. Filing ↗machine: r5 · c35 · span 342095–342104
4Section 08, Sunil AgarwalDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 256,282. Filing ↗machine: span 240649–240656
5Section 08, Kenneth BateDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 177,480. Filing ↗machine: span 243228–243235
6Section 08, Gregg LapointeDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 146,980. Filing ↗machine: span 256201–256208
7Section 08, Jonathan ViolinDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 141,980. Filing ↗machine: span 258783–258790
8Section 08, Michael KishbauchDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 140,980. Filing ↗machine: span 253595–253602
9Section 08, Joanne BeckDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 139,480. Filing ↗machine: span 245831–245838
10Section 08, Fred CalloriDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 135,980. Filing ↗machine: span 248410–248417
11Section 08, Hugh ColeDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 135,730. Filing ↗machine: span 251011–251018
12Section 08, Jill C. MilneDEF 14A2025-04-280001104659-25-040180Section “Director Compensation”. As printed: 0. Filing ↗
13Section 02, Gregg Lapointe 2025-06-11Form 42025-06-120001104659-25-059034Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Sunil Agarwal 2025-06-11Form 42025-06-120001104659-25-059044Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Joanne Beck 2025-06-11Form 42025-06-120001104659-25-058989Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Hugh Cole 2025-06-11Form 42025-06-120001104659-25-059039Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Jonathan Violin 2025-06-11Form 42025-06-120001104659-25-059031Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Kenneth Bate 2025-06-11Form 42025-06-120001104659-25-059042Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Michael Kishbauch 2025-06-11Form 42025-06-120001104659-25-059037Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Fred Callori 2025-06-11Form 42025-06-120001104659-25-058987Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Andrew Komjathy 2026-01-23Form 42026-01-230000905148-26-000319Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Andrea Matthews 2026-01-23Form 42026-01-230000905148-26-000321Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Andrea Matthews 2026-01-23Form 42026-01-230000905148-26-000321Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Jill C. Milne 2026-01-23Form 42026-01-230000905148-26-000322Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Christopher Morabito 2026-01-23Form 42026-01-230000905148-26-000323Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Kenneth Bate 2026-01-23Form 42026-01-230000905148-26-000312Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Joanne Beck 2026-01-23Form 42026-01-230000905148-26-000313Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Michael Kishbauch 2026-01-23Form 42026-01-230000905148-26-000318Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Michael Kishbauch 2026-01-23Form 42026-01-230000905148-26-000318Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Gregg Lapointe 2026-01-23Form 42026-01-230000905148-26-000320Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Joanne Beck 2026-01-23Form 42026-01-230000905148-26-000313Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Joanne Beck 2026-01-23Form 42026-01-230000905148-26-000313Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Joanne Beck 2026-01-23Form 42026-01-230000905148-26-000313Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Noah Clauser 2026-01-23Form 42026-01-230000905148-26-000315Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Noah Clauser 2026-01-23Form 42026-01-230000905148-26-000315Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Andrew Komjathy 2026-01-23Form 42026-01-230000905148-26-000319Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Andrew Komjathy 2026-01-23Form 42026-01-230000905148-26-000319Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Andrew Komjathy 2026-01-23Form 42026-01-230000905148-26-000319Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Gregg Lapointe 2026-01-23Form 42026-01-230000905148-26-000320Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Gregg Lapointe 2026-01-23Form 42026-01-230000905148-26-000320Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Gregg Lapointe 2026-01-23Form 42026-01-230000905148-26-000320Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Gregg Lapointe 2026-01-23Form 42026-01-230000905148-26-000320Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Andrea Matthews 2026-01-23Form 42026-01-230000905148-26-000321Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Jill C. Milne 2026-01-23Form 42026-01-230000905148-26-000322Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Jill C. Milne 2026-01-23Form 42026-01-230000905148-26-000322Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Christopher Morabito 2026-01-23Form 42026-01-230000905148-26-000323Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Benjamin Harshbarger 2026-01-23Form 42026-01-230000905148-26-000317Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Hugh Cole 2026-01-23Form 42026-01-230000905148-26-000316Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Andrew Komjathy 2026-01-23Form 42026-01-230000905148-26-000319Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Joanne Beck 2026-01-23Form 42026-01-230000905148-26-000313Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Hugh Cole 2026-01-23Form 42026-01-230000905148-26-000316Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Hugh Cole 2026-01-23Form 42026-01-230000905148-26-000316Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Hugh Cole 2026-01-23Form 42026-01-230000905148-26-000316Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Fred Callori 2026-01-23Form 42026-01-230000905148-26-000314Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Fred Callori 2026-01-23Form 42026-01-230000905148-26-000314Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Fred Callori 2026-01-23Form 42026-01-230000905148-26-000314Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Kenneth Bate 2026-01-23Form 42026-01-230000905148-26-000312Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Kenneth Bate 2026-01-23Form 42026-01-230000905148-26-000312Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Kenneth Bate 2026-01-23Form 42026-01-230000905148-26-000312Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Kenneth Bate 2026-01-23Form 42026-01-230000905148-26-000312Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michael Kishbauch 2026-01-23Form 42026-01-230000905148-26-000318Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Michael Kishbauch 2026-01-23Form 42026-01-230000905148-26-000318Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Sunil Agarwal 2026-01-23Form 42026-01-230000905148-26-000311Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Sunil Agarwal 2026-01-23Form 42026-01-230000905148-26-000311Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Jonathan Violin 2026-01-23Form 42026-01-230000905148-26-000324Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Benjamin Harshbarger 2026-01-23Form 42026-01-230000905148-26-000317Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Benjamin Harshbarger 2026-01-23Form 42026-01-230000905148-26-000317Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Michael Kishbauch 2026-01-23Form 42026-01-230000905148-26-000318Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Hugh Cole 2026-01-23Form 42026-01-230000905148-26-000316Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Fred Callori 2026-01-23Form 42026-01-230000905148-26-000314Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Fred Callori 2026-01-23Form 42026-01-230000905148-26-000314Insider equity transaction reported since the proxy statement. Filing ↗
77Section 06, 2025 voteForm 8-K2025-06-120001104659-25-058887Item 5.07 · say-on-pay result. As reported: 86.82% (votes for as printed: 43,538,692). Filing ↗
78Section 06, 2024 voteForm 8-K2024-06-060001104659-24-069064Item 5.07 · say-on-pay result. As reported: 88.43% (votes for as printed: 40,882,888). Filing ↗
79Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
80Section 09b board cost (computed)Computed——Cash 444,723 + equity 0 + all other 0 = 444,723, summed across the director compensation table rows.machine: formula: Σ = 444,723
81Edgewise Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047688CEO total compensation as printed in Edgewise Therapeutics, Inc.'s own proxy. As printed: 7,359,546. Filing ↗
82Viridian Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-170001193125-26-160344CEO total compensation as printed in Viridian Therapeutics, Inc.'s own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778
83Astria Therapeutics (subject), Section 10b CEO totalDEF 14A2025-04-280001104659-25-040180CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. Filing ↗machine: r1 · c35 · span 327451–327460
84Savara, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177353CEO total compensation as printed in Savara, Inc.'s own proxy. As printed: 4,845,000. Filing ↗machine: r2 · c30 · span 340387–340396
85Ocugen, Inc., Section 10b CEO totalDEF 14A2026-04-280001140361-26-017260CEO total compensation as printed in Ocugen, Inc.'s own proxy. As printed: 4,841,822. Filing ↗machine: r2 · c22 · span 505124–505133
86Annexon Biosciences, Section 10b CEO totalDEF 14A2026-04-270001140361-26-017085CEO total compensation as printed in Annexon Biosciences's own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214
87Larimar Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001193125-26-163942CEO total compensation as printed in Larimar Therapeutics, Inc.'s own proxy. As printed: 3,526,423. Filing ↗machine: t90 · r3 · c39 · span 812416–812425
88Inozyme Pharma, Inc., Section 10b CEO totalDEF 14A2025-04-290000950170-25-060198CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355
89Foghorn Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-193928CEO total compensation as printed in Foghorn Therapeutics, Inc.'s own proxy. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369
90Adicet Bio, Inc., Section 10b CEO totalDEF 14A2026-04-290001720580-26-000027CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. Filing ↗machine: r2 · c27 · span 482415–482424
91Cue Biopharma, Inc., Section 10b CEO totalDEF 14A2026-03-160001193125-26-108301CEO total compensation as printed in Cue Biopharma, Inc.'s own proxy. As printed: 1,185,639. Filing ↗machine: r2 · c12 · span 458480–458489
92Section 10a, Savara, Inc. reciprocityDEF 14A—0001193125-26-177353Savara, Inc. names Astria Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
93Section 10a, Edgewise Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-047688Edgewise Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Astria Therapeutics. Filing ↗
94Section 10a, Viridian Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-160344Viridian Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Astria Therapeutics. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.